Hyloris Pharmaceuticals buys global rights to CRD-102 from Baker Institute

Hyloris Pharmaceuticals has acquired the global rights from Australia-based Baker Heart and Diabetes Institute (Baker Institute) to CRD-102, a clinical-stage, extended-release Milrinone capsule. CRD-102 is ... Read More